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ABSTRACT
Topoisomerase-II accumulates at centromeres
during prometaphase, where it resolves the DNA
catenations that represent the last link between
sister chromatids. Previously, using approaches
including etoposide-mediated topoisomerase-II
cleavage, we mapped centromeric domains in
trypanosomes, early branching eukaryotes in
which chromosome segregation is poorly under-
stood. Here, we show that in bloodstream form
Trypanosoma brucei, RNAi-mediated depletion of
topoisomerase-IIa, but not topoisomerase-IIb,
results in the abolition of centromere-localized
activity and is lethal. Both phenotypes can
be rescued by expression of the corresponding
enzyme from T. cruzi. Therefore, processes which
govern centromere-specific topoisomerase-II
accumulation/activation have been functionally
conserved within trypanosomes, despite the long
evolutionary separation of these species and differ-
ences in centromeric DNA organization. The vari-
able carboxyl terminal region of topoisomerase-II
has a major role in regulating biological function.
We therefore generated T. brucei lines expressing
T. cruzi topoisomerase-II truncated at the carb-
oxyl terminus and examined activity at centro-
meres after the RNAi-mediated depletion of the
endogenous enzyme. A region necessary for
nuclear localization was delineated to six residues.
In other organisms, sumoylation of topoisomerase-II
has been shown to be necessary for regulated
chromosome segregation. Evidence that we
present here suggests that sumoylation of the
T. brucei enzyme is not required for centromere-
specific cleavage activity.
INTRODUCTION
Topoisomerase II (Topo-II) plays a central role in
chromosome biology and has been implicated in segrega-
tion in organisms ranging from yeast to vertebrates. After
replication, sister chromatids remain attached, partly
through strand catenation at centromeres, as cells enter
mitosis (1–4). The cell-cycle-speciﬁc accumulation of
Topo-II at centromeres is a major regulator of sister chro-
matid cohesion and is required for ordered segregation
(5–7). Several reports have implicated sumoylation of
Topo-II as a prerequisite for faithful segregation (8–12).
Speciﬁcally, SUMO (small ubiquitin-like modiﬁer) E3
ligases appear to be required for localization of Topo-II
to the inner centromeric domains, where the enzyme
resolves the catenated centromere-associated DNA
strands that are thought to provide the ﬁnal structural
continuity between sister kinetochores (1). Topo-II
catalysed decatenation involves double-stranded DNA
cleavage, passage of the uncut duplex through the break,
and re-ligation to repair the lesion. The Topo-II inhibitor
etoposide blocks this re-ligation step, resulting in DNA
breaks at sites speciﬁed by Topo-II binding (13).
Evidence for centromeric sequestration of Topo-II
includes the observation that etoposide-mediated
cleavage sites in human chromosomes occur within
the a-satellite arrays of centromeric DNA (14–16)
and that hairpin structures formed by the a-satellite
DNA can be cleaved by Topo-IIa (17). In the malaria
parasite Plasmodium falciparum, Topo-II activity
concentrates at chromosomal loci which encompass 2-kb
*To whom correspondence should be addressed. Tel: +44 20 7927 2330; Fax: +44 20 7636 8739; Email: john.kelly@lshtm.ac.uk
Present addresses:
Samson O. Obado, Laboratory of Cellular and Structural Biology, Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.
Christopher Bot, School of Biological and Chemical Sciences, Queen Mary, University of London, Mile End Road, London E1 4NS, UK.
Published online 22 September 2010 Nucleic Acids Research, 2011, Vol. 39, No. 3 1023–1033
doi:10.1093/nar/gkq839
 The Author(s) 2010. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.AT-rich domains previously suggested as candidates for
centromere location (18).
Trypanosomatids diverged early in eukaryotic evolu-
tion. This family includes the African trypanosome
Trypanosoma brucei and the American trypanosome
T. cruzi, insect-transmitted protozoan parasites of major
medical and veterinary importance. Genome organization
and expression in trypanosomes differ from other eukary-
otes (19). Protein coding genes lack individual RNA
polymerase II-dependent promoters, transcription is
polycistronic and all mRNAs are post-transcriptionally
modiﬁed by addition of a 50-spliced leader RNA.
Directional gene clusters often stretch over hundreds of
kilobases. Trypanosomes exhibit signiﬁcant intra-strain
variation in chromosome size, and although diploid,
chromosome homologues can differ considerably in
length (20). Completion of the trypanosome genome
projects (21,22) did not lead to the identiﬁcation of
chromosomal loci that might have a role in segregation.
Progress in this area has been further hampered by
the small size of trypanosome chromosomes (typically
0.5–5Mb), the fact that chromatin does not condense
during mitosis, and the lack of robust systems for
synchronizing the cell cycle. Several observations hint
that segregation may differ from the mammalian host.
The number of kinetochores seems to be less than the
number of chromosomes (23,24), trypanosomes lack
obvious equivalents of the ‘core’ centromeric proteins
and few other factors involved in kinetochore assembly/
function have been conserved (22,25). Trypanosomes even
lack an obvious orthologue of the centromeric histone
CenH3, which was thought to be ubiquitous in eukaryotes
(26). Trypanosoma brucei does express a histone H3
variant, but it is non-essential, is enriched in the telomeric
domains, and lacks signatures diagnostic of CenH3, such
as the extended loop 1 region (27).
Recently, we reported the use of telomere-associated
chromosome fragmentation to show that the regions
required for mitotic stability of T. cruzi chromosomes 1
and 3 centre on loci which encompass GC-rich transcrip-
tional ‘strand-switch’ domains (11 and 16kb, respectively)
composed predominantly of degenerate retroelements
(28). We also found, using etoposide-mediated cleavage,
that the predominant sites of chromosomal Topo-II
activity can be mapped to these loci (29). Based on these
independent approaches, applied to two separate chromo-
somes, we proposed this type of sequence organization as
a paradigm for centromeric DNA in T. cruzi. In the
T. brucei ‘megabase-sized’ chromosomes, Topo-II
activity was also focused at single loci, which encompass
regions between directional gene clusters that contain
transposable elements. Unlike the situation in T. cruzi,
these putative centromeric regions also contain arrays
of AT-rich repeats stretching over several kilobases.
The ﬁnal step of sister chromatid separation during
early anaphase, involves the removal of centromeric
cohesin by separase and the resolution by Topo-II of the
remaining DNA catenations (30). In higher eukaryotes,
considerable progress has been made in dissecting the
processes involved in the cell-cycle-dependent centromeric
localization/activation of Topo-II (1,3,9,11,12).
In trypanosomes however, the mechanisms that mediate
this crucial stage in chromosome segregation are
unknown. Two nuclear Topo-II isoforms have been
identiﬁed in T. brucei (31). The corresponding genes are
arranged as a tandem array and have been designated a
and b. The a-isoform is essential for proliferation of
procyclic parasites (the form found in the insect vector),
while the b-isoform appears to be non-essential in this
life-cycle stage (31). Here, we have exploited the genetic
tractability of T. brucei to identify which Topo-II isoform
is active at centromeres in bloodstream form parasites
(BSF) and, to investigate the role of the divergent
carboxyl terminal region.
MATERIALS AND METHODS
Parasite culturing and preparation of nucleic acids
Trypanosoma brucei BSFs (Lister 427, clone 221a and
derivatives thereof) were grown at 37 C under a
5% CO2 atmosphere in modiﬁed Iscove’s medium (32).
For RNAi experiments we used the BSF T. brucei 2T1
line that constitutively expresses the tetracycline repressor
protein (33) and which a tetracycline-regulatable RRNA
promoter expression cassette had been integrated into
chromosome 2a (34). Trypanosoma cruzi epimastigotes
(CL Brener) were cultured at 27 C as described previously
(35). Genomic DNA was extracted using DNeasy tissue
mini-kits (Qiagen). Intact chromosomes, extracted by
an agarose-embedding technique (28), were separated
with a CHEF Mapper System (Bio-Rad) using an auto-
algorithm set to the appropriate molecular mass range.
RNA was prepared using RNeasy mini-kits (Qiagen).
Generation of constructs used in RNAi and localization
experiments
All primers used in this work are described in
Supplementary Table S1. For stem-loop constructs used
in the depletion of the T. brucei Topo-IIa transcript, frag-
ments derived from nt 3629 to 4286 of the gene sequence
were ampliﬁed by PCR and inserted in opposite orienta-
tions either side of the 468-bp lacZ stuffer fragment of the
pRPa
iSL construct (34). Electroporation of BSF T. brucei
(2T1 line) with linearized DNA was carried out by using a
Gene Pulser II (BioRad) and cloned transfectants selected
with 2.5mgml
 1 hygromycin as described (34). For the
Topo-IIb experiment, fragments were derived from nt
3743 to 4369 of the gene sequence (31). Transformed
cells were analysed initially by comparing growth in the
presence/absence of tetracycline (1mgml
 1) as outlined
(36). All experiments were performed using cloned cells,
and the results veriﬁed with independently derived lines.
To complement the RNAi phenotype, we integrated full
length or truncated copies of the T. cruzi Topo-II gene
into the T. brucei tubulin array using a derivative of the
pTUB-EX vector (37), which contains a blasticidin-
resistance gene. Selection was at 10mgml
 1. Truncated
forms of the T. cruzi gene used in the complementation
experiments (Figure 4) were generated by restriction diges-
tion, utilizing a Mlu I site in the gene and an Asc I site in
the vector adjacent to the cloning site, and insertion of
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lish the sub-cellular location of T. cruzi Topo-II and
truncated derivatives in T. brucei, we isolated a DNA
fragment encoding 12 copies of the c-Myc epitope from
vector pNAT
x12M (34) and inserted it in-frame at the
30-end of the T. cruzi Topo-II gene in pTUB-EX-Bla,
creating an Fse I site at the junction. Truncated forms
of the T. cruzi Topo-II tagged gene could then be
generated by direct replacement of 30-segments of the
full length copy in this vector using the Mlu I and Fse I
sites. The resulting linearized constructs could be targeted
to the T. brucei tubulin locus. To demonstrate that the
carboxyl terminal tag did not affect function, we ﬁrst
deleted one copy of T. brucei Topo-II by gene disruption
using a blasticidin selectable marker. The second allele
was then tagged at the 30-end with the 12 c-Myc
epitope by a gene knock-in strategy, using the fragments
described (Supplementary Table S1 and Figure S3) and
the hygromycin-resistance gene as a marker (selection at
2.5mgml
 1). For the SUMO knockdown experiments,
copies of the full length T. brucei gene (345bp;
Tb927.5.3210) were cloned in opposite orientations into
the pRPa
iSL vector.
Oligonucleotide-directed in vitro mutagenesis was per-
formed using the Stratagene QuikChange mutagenesis kit,
following the manufacturer’s instructions. Brieﬂy, ampli-
ﬁcations were carried out in 50ml volumes, with the cloned
T. cruzi Topo-II gene as the template. The reaction con-
sisted of one cycle of 95 C for 30s, then 16 cycles of 95 C
for 30s, 55 C for 1min and 68 C for 6min. Following
this, 10U of Dpn I was added to the reaction mixture to
digest the parental double-stranded DNA. A 1-ml aliquot
of the Dpn I-digested PCR product was then used to
transform E. coli. Primers used to generate each of the
desired mutations are described in Supplementary
Table S1. Mutations were conﬁrmed by sequencing.
Immunoprecipitation of c-Myc tagged T. brucei Topo-IIa
In total, 2 10
8 BSF T. brucei in the logarithmic phase of
growth were pelleted and mechanically lysed on ice after
30-min incubation in RIPA buffer (Sigma), supplemented
with a protease inhibitor cocktail (2.5mM 1,10-
phenantroline, 5mM pepstatin A, 1mM phenylmethyl-
sulfonyl ﬂuoride, 20mM N-ethylmaleimide, plus Roche
protease inhibitor tablets). After lysis, four volumes of
non denaturing buffer (20mM Tris–HCl, pH 8; 137mM
NaCl; 10% glycerol; 1% Nonidet P-40; 2mM EDTA),
supplemented with the protease inhibitor cocktail, were
added and the insoluble material pelleted at 14000 g
for 10min. The supernatant was incubated with 30ml
Prot G-Agarose beads under rotation for 30min. mAb
anti-Myc tag (Millipore), diluted 1:250, was added to
cleared extract which was rotated for 2h. An amount of
30ml of pre-equlibrated Prot G-Agarose beads were then
added and incubated for a further 3h. The beads were
pulled down by centrifugation at 15000 g for 30s. The
supernatant was snap frozen and the beads washed with
4 1ml of non denaturing buffer (5min each, under
rotation). All steps were performed at 4 C. After
washing, the pulled down material was eluted with 30ml
of 3 SDS–PAGE loading buffer and boiled for 5min
prior to fractionation by electrophoresis.
Immunoﬂuorescence microscopy
Trypanosomes in logarithmic growth phase were ﬁxed in
suspension with 2% paraformaldehyde in PBS and
air-dried on glass slides as described (38). Cells were
labelled with mouse anti-c-Myc (9E10) antibody (Santa
Cruz Biotechnology) (diluted 1:50) for 1h and secondary
antibody (AlexaFluor 488-conjugated goat anti-mouse
antibodies; Molecular Probes) (diluted1:400) for 30min
in PBS-S, with 2% horse serum. DNA was stained with
DAPI. Slides were examined on a Zeiss LSM 510 confocal
laser-scanning microscope.
Anti-SUMO antibodies
The sequence corresponding to TcSUMO was cloned into
the bacterial expression vector pET28 (Novagene) and
tagged, both at the amino and the carboxyl terminus,
with a His6 tag. Escherichia coli BL21 cells were trans-
formed with this construct and protein expression was
induced with 1mM IPTG for 3h. Recombinant
TcSUMO was puriﬁed using Ni-NTA (Invitrogen)
afﬁnity chromatography and injected into rabbit using
standard protocols.
RESULTS
Topo-IIa is essential in bloodstream form T. brucei and
is responsible for centromere-speciﬁc topoisomerase
cleavage activity
The sequences of the two T. brucei Topo-II nuclear
isoforms are highly conserved over most of their length
(31). However, the carboxyl terminal regions (CTRs)
share only 23% identity. In other organisms, this highly
divergent CTR is non-essential for enzyme activity
(39,40), but has been shown to have an important role
in modulating cellular function (41–43). The CTR of
the T. brucei a–isoform (amino acids 1165–1455) contains
three putative bipartite nuclear localization signals
(identiﬁed in Figure 1), a short acidic residue-rich
region of unknown function adjacent to the carboxyl
end (amino acids 1431–1448), and a carboxyl terminal
tripeptide (FSD), which is conserved throughout the
trypanosomatids.
To determine which of the Topo-II isoforms is
enzymatically active at centromeres in BSF T. brucei,w e
used a tetracycline-inducible RNAi system to selectively
deplete each of the corresponding transcripts. The system
is based on integration of a ‘stem-loop’ construct into the
RRNA locus on chromosome 2a, which facilitates
the tightly regulated expression of intramolecular
dsRNA containing oppositely orientated isoform-speciﬁc
sequences [Figure 1; see ‘Materials and Methods’ section
(34)]. When Topo-IIa was targeted using this approach,
there was a major decline in mRNA levels within 24h of
tetracycline addition, followed by cessation of parasite
growth and cell death (Figure 2A). This growth arrest
was associated with a range of cellular abnormalities,
Nucleic Acids Research,2011, Vol.39, No. 3 1025including enlargement of the nucleus and uncoupling of
the cell-cycle-speciﬁc segregation of the mitochondrial and
nuclear genomes. This gave rise to cells with multiple kin-
etoplasts (the mitochondrial genome) (Figure 2B). To in-
vestigate if these defects were associated with loss of
centromeric-speciﬁc topoisomerase activity, we used
etoposide-mediated cleavage as a marker. The procedure
involved etoposide-treatment of BSF parasites (typically
100mM for 30min) 28h after the induction of RNAi, iso-
lation of chromosomal DNA, fractionation by
contour-clamped homogenous electric ﬁeld gel electro-
phoresis (CHEFE) and Southern analysis. Examination
of chromosomes where RNAi was not induced revealed
the characteristic cleavage products arising from
etoposide-mediated inhibition of the DNA ligation step
in the Topo-II decatenation reaction (13) (lane 2,
Figure 2D). In cells where the Topo-IIa transcript had
been depleted, this activity was completely abolished
(lane 3). When Topo-IIb was targeted, there was no re-
duction in the growth rate of BSF parasites (Figure 2C),
similar to an observation previously made with procyclic
parasites (31). Furthermore, centromere-associated topo-
isomerase activity was not affected (lane 5, Figure 2D).
Therefore, depletion of Topo-IIa, but not b, is lethal
and growth cessation parallels the loss of centromere–
localized enzyme activity.
Expression of T. cruzi Topo-II can rescue bloodstream
form T. brucei from the effects of Topo-IIa knockdown
To determine the extent of functional conservation of
centromere-speciﬁc Topo-II activity within trypanosomes,
we investigated if the T. cruzi enzyme (which is an
orthologue of the a-isoform) could complement
RNAi-dependent depletion of the corresponding tran-
script in BSF T. brucei. These parasites diverged
between 100 and 200 million years ago (44) and there
are distinct differences in the organization and compos-
ition of centromeric DNA in the two species (28,29).
Furthermore, unlike T. brucei, T. cruzi does not have
the repertoire of genes necessary for a functional RNAi
system. We therefore inserted the T. cruzi Topo-II gene
into the T. brucei tubulin array on chromosome 1 in the
engineered cell line containing the inducible-RNAi ma-
chinery (34; see ‘Materials and Methods’ section).
Constitutive expression of the T. cruzi gene in these cells
was found to rescue the lethal phenotype that results from
depletion of the endogenous transcript (Figure 3A). In
addition, the pattern of etoposide-mediated cleavage of
chromosomal DNA was the same as that generated by
the T. brucei enzyme (Figure 3B). It can be inferred there-
fore, that the major mechanisms controlling centromeric-
speciﬁc Topo-II cleavage activity have been functionally
conserved between trypanosome species.
The CTR of Topo-II, although highly divergent, plays a
major role in functional regulation. Properties associated
with this region, in organisms ranging from yeast to
humans, include nuclear localization (40,41),
cell-cycle-speciﬁc phosphorylation (45), SUMO modiﬁca-
tion (10) and chromosomal targeting during mitosis (42).
The functional equivalence of the T. brucei and the
T. cruzi enzymes was therefore exploited to investigate
how this region might affect biological activity. First, we
generated a truncated version of the T. cruzi Topo-II in
which the 44 amino acids proximal to the CTR, including
the highly acidic stretch of residues and the conserved
terminal tripeptide, had been deleted (Figures 1 and 4A).
This modiﬁed gene was inserted into the tubulin array in
BSF T. brucei (see ‘Materials and Methods’ section).
When the endogenous Topo-IIa transcript was depleted
by RNAi, the truncated T. cruzi enzyme was found to
rescue the growth arrest phenotype (Supplementary
Figure S1). In addition, the pattern of chromosomal
cleavage resulting from etoposide treatment was the
Figure 1. The carboxyl terminal region (CTR) of T. cruzi Topo-II (Tc) and T. brucei Topo-IIa (Tb). The black arrow identiﬁes the start of the CTR
(residue 1165, T. brucei Topo-IIa; 31) and putative monopartite and bipartite nuclear localization signals (as predicted by PSORT II) are shown in
blue. Residues marked in turquoise conform to consensus sumoylation motifs (48). The acidic residue-rich domain adjacent to the carboxyl terminus
is highlighted in red (amino acids 1431–1448 in T. brucei Topo-IIa). The numbered red triangles identify the carboxyl termini of the truncated
T. cruzi enzymes used in the complementation experiments. Lettered triangles identify termini of truncated T. brucei enzymes. The region of the
T. brucei sequence used as a species-speciﬁc probe, and in RNAi experiments, is underlined. The T. cruzi Topo-II-speciﬁc probe was derived from the
DNA sequence corresponding to residues 1226–1484. Regions of identity are shaded.
1026 Nucleic Acids Research, 2011,Vol.39, No. 3same as with wild-type cells. Therefore, neither the
acidic-rich stretch of residues nor the conserved terminal
tripeptide in the T. cruzi enzyme are required for this
centromere-speciﬁc activity (and by implication nuclear
localization/retention), and do not have an alternative
role that is required for cell viability or growth under
these conditions.
To assess the role of other sections of the CTR in
Topo-II function, we generated a series of deletion
constructs of the T. cruzi gene (Figures 1 and 4A) and
expressed the resulting proteins in the BSF T. brucei as
described above. In each case we examined the resulting
cell lines for effects on growth and centromere-associated
topoisomerase activity following the induction of RNAi
(Supplementary Figure S1). The experiments showed that
deletion of the 6 amino-acid segment that differentiates
the truncated proteins generated by constructs 2 and 3
(VKKEAA) was sufﬁcient to block rescue of the growth
phenotype (Figure 4D). These residues are situated imme-
diately adjacent to a predicted bipartite NLS (Figure 1)
and could inﬂuence the functionality of the signal domain.
Deletion of this 6 amino-acid region was also associated
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Figure 2. Effect of RNAi-mediated down-regulation of Topo-IIa and b on bloodstream form T. brucei.( A) Growth of tetracycline-treated (red line)
and non-treated T. brucei (black line) containing an integrated construct that facilitates induction of RNAi targeted at Topo-IIa (see ‘Materials and
Methods’ section). The inset shows the relative levels of Topo-IIa, b and tubulin mRNAs 24h after tetracycline addition, as assessed by northern
blotting. The Topo-IIa probe corresponds to the region of the CTR underlined in Figure 1. For the Topo-IIb probe, see ‘Materials and Methods’
section. (B) Morphology of BSF parasites following the induction of the Topo-IIa stem-loop transcript (upper micrographs, phase images; lower
micrographs, DAPI-stained images). The time zero images show two parasites, each with a single nucleus (N) and kinetoplast (K). Following
tetracycline treatment, kinetoplast division continues, but nuclear division is disrupted. (C) Parasite growth following induction of the Topo-IIb
stem-loop transcript. The red (tetracycline-treated) and black (non-treated) lines are superimposable. The inset shows transcript levels 24h after
treatment of parasites with tetracycline, as in (A). (D) Centromere-speciﬁc Topo-II activity in chromosome 5 assessed by etoposide-mediated
cleavage. Parasites were treated as described below and chromosomal DNA was separated by CHEFE, Southern blotted and hybridized with the
probe indicated (Tb927.5.560). Lane 1, wild-type cell line without tetracycline ( ) or etoposide ( ) treatment; lane 2, Topo-IIa RNAi cell line
without tetracycline ( ), but treated with etoposide for 30min (+); lane 3, Topo-IIa RNAi cell line treated with tetracycline (+) and etoposide (+);
lane 4, Topo-IIb RNAi cell line without tetracycline ( ), but treated with etoposide (+); lane 5, Topo-IIb RNAi cell line treated with tetracycline (+)
and etoposide (+). The 0.65-Mb product results from cleavage in the centromeric domain (indicated by black sphere in diagram). Centromeric
activity is lost when Topo-IIa, but not Topo-IIb, is depleted. A background of plasmid DNA which co-puriﬁed with the probe, hybridizes faintly
with the RNAi construct integrated into chromosome 2a (marked by an asterisk).
Nucleic Acids Research,2011, Vol.39, No. 3 1027with loss of centromeric activity, as judged by
etoposide-mediated cleavage (Figure 4C). To investigate
this further, we generated epitope-tagged (c-Myc)
versions of the relevant truncated enzymes and expressed
them in the BSF T. brucei lines. Enzymes containing the
6 amino-acid segment were found to be localized to the
parasite nucleus (Figure 4E). In the absence of this
sequence, the enzyme was distributed throughout the
cytosol. This short region is therefore required for
nuclear targeting of the T. cruzi enzyme, or for its reten-
tion within the nucleus.
We also investigated if the corresponding region in the
T. brucei enzyme has a role in localization. To address
this, we generated truncated c-Myc tagged versions of the
T. brucei gene analogous to deletion constructs 2 and 3
of the T. cruzi enzyme (Figures 1 and 4A). These were
inserted into the tubulin locus as above and the endogen-
ous enzyme depleted by RNAi. Sequences deleted from
the truncated genes were used to generate the stem-loop
RNAi constructs. In both instances, induction of RNAi
resulted in cessation of growth after 24h, followed by cell
death. Examination of the cells indicated that both
truncated enzymes were cytosolic and excluded from
the nucleus (Supplementary Figure S2A and B).
Therefore, the nuclear localization signal on the
T. brucei Topo-IIa does not include this 6 amino-acid
sequence and must be located closer to the carboxyl
terminus.
To conﬁrm that the carboxyl c-Myc sequence did not
perturb enzyme function and localization, we used a ‘gene
knock-in’ approach to tag one of the Topo-II alleles with
a sequence encoding the epitope, using a cell line in which
the other allele had been disrupted by insertion of a
blasticidin selectable marker. These cells were found to
be viable and displayed a phenotype indistinguishable
from that of the wild-type, with the tagged enzyme
localized to the nucleus (Supplementary Figure S3).
Is sumoylation of Topo-II required for centromeric
activity in trypanosomes?
SUMO modiﬁcation of Topo-II is required for regulated
chromosomal segregation in organisms ranging through
mammals, amphibians and budding yeast (8–12,46,47).
We therefore investigated if this modiﬁcation has a role
in Topo-II activity in trypanosomes. First, we attempted
to detect sumoylated Topo-IIa, making use of the
T. brucei cell line expressing c-Myc tagged Topo-IIa
(above). After immunoprecipitation with a c-Myc mono-
clonal antibody (see ‘Materials and Methods’ section), a
150-kDa band corresponding to the tagged enzyme could
be readily visualized on a western blots (Figure 5A).
However, neither this, nor higher molecular mass bands
could be detected when blots were probed with an
antibody raised against trypanosome SUMO.
Sumoylation of Topo-II has been identiﬁed as a low
abundance event in vivo (8,10). As an alternative
approach of investigation, we therefore examined
T. cruzi Topo-II and T. brucei Topo-IIa for sequences
conforming to the sumoylation consensus sequence
cKXE, where c corresponds to a large hydrophobic
amino residue (48). Two putative sumoylation motifs
were detected, both at corresponding sites in the CTR
(marked in turquoise, Figure 1). By way of comparison,
there are three functional sumoylation sites in the CTR of
Saccharomyces cerevisiae Topo-II (10). In the case of the
T. cruzi enzyme, one of the sumoylation motifs (VKKE) is
located within the sequence that we had shown to be
necessary for nuclear localization (residues 1332–1337).
To assess if these motifs have a biological function, we
used site-directed mutagenesis to alter the lysine residues
which would act as the acceptor for the covalent attach-
ment of SUMO. We integrated full length T. cruzi Topo-II
genes containing either single or double mutations
(Table 1) into the T. brucei genome. Using the approach
described above, we then depleted the endogenous
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induction of RNAi targeted at the Topo-IIa gene. Black line,
non-treated parasites; red line, tetracycline treated; dashed red line,
tetracycline treated cells expressing a copy of the T. cruzi Topo-II
gene. Northern blots show the relative levels of expression of the
T. brucei (Tb) and T. cruzi (Tc) genes (inset). Ethidium bromide
stained RRNA is shown as a loading control. (B) Centromere-speciﬁc
activity of T. cruzi Topo-II expressed in BSF T. brucei. Lane 1,
wild-type cell line, without tetracycline ( ) or etoposide ( ) treatment;
lanes 2, 3 and 4, T. brucei Topo-IIa RNAi cell line treated with
tetracycline for 0, 16 and 28h, and then treated with etoposide (+)
for 30min; lane 5, T. brucei Topo-IIa RNAi cell line expressing
T. cruzi Topo-II, induced with tetracycline for 28h, and then treated
with etoposide (+). Parasite DNA was separated by CHEFE and the
chromosome 3 probe Tb927.3.3550 was used.
1028 Nucleic Acids Research, 2011,Vol.39, No. 3Topo-IIa using RNAi and investigated whether the
mutated genes could complement the resulting phenotype.
In each case, the modiﬁed genes were able to rescue the
cells from growth cessation and maintain centromere-
speciﬁc Topo-II activity, as judged by etoposide-mediated
cleavage of chromosomal DNA (Supplementary
Figure S4).
It remained possible that Topo-II could be sumoylated
at sites other than the consensus lysine acceptor residues.
We therefore addressed the role of SUMO activity
using an alternative approach. Mammals express at
least three SUMO proteins (49). In trypanosomes,
there is a single gene (Tb927.5.3210 in T. brucei), which
has been shown to be essential in procyclic forms of
the parasite (50). To further investigate if there was an
association between SUMO and the centromeric activity of
Topo-II in trypanosomes, we assessed the phenotype
of BSF T. brucei following RNAi-mediated depletion
of the SUMO transcript. The parasites were found to
stop dividing after 24h, but unlike cells where Topo-IIa
had been depleted, signiﬁcant cell death was not observed
until beyond the 96-h time point (cf Figures 2A and 5B).
Furthermore, in contrast to Topo-IIa depletion,
nuclear division appeared to continue in the absence of
cytokinesis, with many cells displaying a multi-nucleated
phenotype (cf Figures 2B and 5E). The SUMO transcript
was almost completely depleted within 24h of RNAi
induction (Figure 5B). However, it took at least 48h
until there was an effect on the global sumoylation
pattern (Figure 5C). Western analysis of parasite lysates
identiﬁed a range of sumoylated proteins, with varying
intensity. To investigate the effect of SUMO knock-
down on centromere-speciﬁc Topo-IIa activity, we
used etoposide-mediated cleavage. We found that
there was no apparent reduction in the extent of this
activity following RNAi-mediated depletion of SUMO
(Figure 5D). Therefore, the growth cessation caused
by down-regulation of SUMO does not appear to
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Figure 4. Complementation of the T. brucei Topo-IIa RNAi phenotype by expression of truncated versions of the T. cruzi enzyme. (A) Deletion
constructs (1–5) used in these experiments. The scale diagram is shown to illustrate the domains of the full length T. cruzi Topo-II (1484 residues)
(31). The expanded CTR shows the location of one putative monopartite and three bipartite nuclear localization signals (blue), and the acidic
residue-rich domain (red) (see Figure 1 for sequences). Constructs 1–5 were generated and expressed in BSF T. brucei as described (‘Materials and
Methods’ section). (B–E) The truncated proteins expressed by constructs 1 and 2, but not constructs 3, 4 or 5 rescued the growth phenotype
associated with RNAi-mediated depletion of T. brucei Topo-IIa RNA. (B) Northern blots of the RNAi cell line expressing truncated T. cruzi Topo-II
products (lane 1, no tetracycline treatment; lane 2, treated with tetracycline for 24h). Ethidium bromide stained RRNA was used as the loading
control. The lower panel shows expression of the T. cruzi transcript. (C) Southern blots of CHEFE gels. Tracks are as follows; lane 1, wild-type cells;
lane 2, non-tetracycline-treated cells as in the northern blots, treated with etoposide for 30min; lane 3, cells treated with both tetracycline and
etoposide. The chromosome 3 (1.8/2.0Mb) probe identiﬁes the 0.8Mb cleavage product indicative of centromere-speciﬁc topoisomerase activity
(Figure 3). (D) Growth of T. brucei RNAi cell lines expressing T. cruzi deletion constructs. The black line corresponds to non-treated cells and the
red dashed line to tetracycline-treated. Growth (y-axis) is represented by cumulative cell density (cellsml
 1). Similar data sets were generated for
constructs 1, 4 and 5 (Supplementary Figure S1). (E) Sub-cellular localization in BSF T. brucei of truncated versions 2 and 3 of T. cruzi Topo-II
tagged at the carboxyl terminus with a c-Myc epitope (see ‘Materials and Methods’ section). DNA staining with DAPI (red) identiﬁes the parasite
nucleus (larger structure) and kinetoplast (smaller). The product of construct 2 (green staining) localizes to the nucleus, whereas the product of
construct 3 is cytosolic.
Nucleic Acids Research,2011, Vol.39, No. 3 1029correlate with perturbation of the centromere-localized
cleavage activity of Topo-IIa. Furthermore, cessation of
cell growth does not, of itself, result in reduction or loss of
this activity.
DISCUSSION
Almost all studies on chromosome segregation have
focussed on representatives of two of the ‘supergroups’
that constitute eukaryote phylogeny; the Opisthokonta
(which include fungae, insects and mammals) and the
Archaeplastida (algae and plants). Studies on the other
large ‘supergroups’, which encompass the majority of eu-
karyotic species, such as the Chromalveolata (includes the
apicomplexan parasites) and the Excavata (includes the
trypanosomatid parasites) have been limited. As a result,
our understanding of segregation and the mechanisms
involved does not take into account the extent of eukary-
otic diversity. Topo-II plays a critical role at centromeres
during mitosis and is one of the few proteins central to
sister chromatid resolution that has been identiﬁed and
studied in trypanosomes. Topoisomerases are widely con-
sidered as important targets for cancer chemotherapy,
with a series of inhibitors now at various stages in the
clinical trial pipeline (51). In addition, parasite topo-
isomerases have also been identiﬁed as targets for drug
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Figure 5. Is sumoylation required for activity of Topo-IIa in BSF T. brucei?( A) Analysis of immunoprecipitated Topo-IIa by western blotting. Lane
1, lysate from cells in which Topo-IIa has been tagged with a carboxyl terminal c-Myc epitope (see ‘Materials and Methods’ section, Supplementary
Figure S3); lane 2, material obtained following immunoprecipitation with anti-c-Myc monoclonal antibody. Blots were probed with c-Myc or SUMO
anti-sera as indicated. (B) Growth of tetracycline-treated (red line) and non-treated T. brucei (black line) containing an integrated construct that
facilitates RNAi targeted at the SUMO transcript (see ‘Materials and Methods’ section). The inset shows the relative levels of SUMO and tubulin
mRNAs in wild-type cells and cells transformed with the RNAi construct, before and after (24h) tetracycline addition, as assessed by northern
blotting. (C) Proﬁle of sumoylated proteins in BSF T. brucei at various times (24–72h) after tetracycline treatment. Protein samples were analysed by
western blotting using an anti-SUMO antibody (see ‘Materials and Methods’ section). An antibody against T. brucei BiP was used as a loading
control (lower panels). (D) Etoposide-mediated cleavage of chromosomal DNA in cells after induction of RNAi targeted at SUMO. Chromosomal
DNA was fractionated by CHEFE, Southern blotted and hybridized with a probe speciﬁc to chromosome 3 (as in Figure 3B). Lane 1, wild-type cell
line without tetracycline ( ) or etoposide ( ) treatment; lanes 2, 3 and 4, T. brucei SUMO RNAi cell line induced with tetracycline for 0, 48 and
72h, and then treated with etoposide (+) for 30min. (E) Morphology of BSF parasites following induction for 48h of the SUMO stem-loop
transcript. DNA was visualized by DAPI staining (see ‘Materials and Methods’ section). Nuclear (N) and kinetoplast (K) DNA are indicated.
Table 1. Mutations generated to investigate the functional signiﬁcance
of putative sumoylation motifs in T. cruzi Topo-II
Wild-type
motif sequence
Mutated motif
Sequence
Complements
TbTopo-IIa depletion
VKKE1335 VAKE YES
VKKE1335 VAQE YES
IKTE1215 IATE YES
VKKE and IKTE VAKE and IATE YES
The location of each motif in the sequence is indicated (see also
Figure 1). Residues altered are shown in bold and underlined.
Mutated genes were inserted into the T. brucei tubulin locus. The en-
dogenous enzyme was then depleted using RNAi and the growth
phenotype and effect on centromere-speciﬁc topoisomerase cleavage
activity was assessed (see ‘Materials and Methods’ section).
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parasite-speciﬁc proﬁles (52).
Trypanosoma brucei contain genes for two nuclear
Topo-II isoforms (31). These have been designated a
and b, although they do not correspond directly with the
mammalian nuclear Topo-II isoenzymes, which have been
given the same nomenclature. The b gene appears to be
speciﬁc to African trypanosomes, in that it is absent from
the other trypanosomatids T. cruzi and Leishmania, where
the single nuclear Topo-II genes are orthologues of the
a-isoform (31). We report here that in BSF T. brucei,
the b gene does not have an obvious role in chromosome
segregation, and that the a gene is essential for both cell
viability and centromere-associated cleavage activity
(Figure 2). Furthermore, in cells where Topo-IIa has
been depleted, we have shown that expression of the
T. cruzi Topo-II gene can complement both of the
observed phenotypes (Figure 3). These experiments there-
fore indicate that any regulatory motifs or residues
required for cell-cycle-dependent localization and/or acti-
vation of Topo-II at centromeres, must be functionally
conserved, despite the long evolutionary separation of
the two trypanosome species and differences in the organ-
ization of their centromeric domains (29).
The CTR of eukaryotic Topo-II has a major role in
specifying and regulating aspects of biological function
(39–41,43,53), including sub-cellular location. In T. cruzi
Topo-II, we identiﬁed a 6 amino-acid region in the CTR
that is required for nuclear sequestration (Figure 4). In
T. brucei Topo-IIa, the corresponding sequence does not
have a role in nuclear targeting or retention. This differ-
ence could reﬂect that in the T. cruzi enzyme, the 6 amino
acids lie immediately adjacent to an NLS whose recogni-
tion by the nuclear import machinery may be perturbed
when these residues are deleted. In T. brucei, the determin-
ant of nuclear localization is located closer to the carboxyl
terminus, in a region that contains an element with the
hallmarks of a bipartite NLS (residues 1403–1421), two
clusters of basic amino acids separated by  10 residues
(Figure 1). Despite this difference in NLS location, the
T. brucei nuclear import machinery is able to facilitate
sequestration of the T. cruzi enzyme. Our results also
show that the signal(s) required for cell-cycle-dependent
centromere-speciﬁc accumulation/activation of the
T. cruzi Topo-II cannot be located between the NLS
and the carboxyl terminus (residues 1338–1484), since
deletion of this region does not appear to affect the
function of the enzyme.
Recent studies in a number of organisms have
demonstrated that SUMO modiﬁcation of Topo-II is
necessary for centromeric localization and ordered
chromosome segregation (8–12). For example, in mice
depleted of RanBP2, a nucleoporin with SUMO E3
ligase activity, Topo-II fails to accumulate at inner centro-
meres where decatenation activity is required for the reso-
lution of sister chromatids (12). Similarly in budding
yeast, SUMO E3 ligase activity is necessary for Topo-II
targeting to the pericentromeric regions of chromosomes
prior to mitosis, and for the ﬁdelity of chromosome trans-
mission (10). In trypanosomes, our data suggest that
mechanisms other than sumoylation are involved in
regulating the centromeric-speciﬁc activity of Topo-II.
First, we could detect no evidence from pull-down experi-
ments that the enzyme is sumoylated (Figure 5A); second,
mutation of the only putative SUMO acceptor lysines in
Topo-II had no observable effect on functional activity
(Table 1, Supplementary Figure S4); and third, RNAi-
mediated SUMO depletion did not perturb centromere-
speciﬁc topoisomerase cleavage activity, even after cell
division has been disrupted (Figure 5B–E). While none
of these experiments of themselves exclude unequivocally
a role for sumoylation in centromeric-speciﬁc activity of
Topo-II, in combination they provide strong evidence that
this modiﬁcation is not involved.
Sumoylation of mammalian Topo-II is thought to fa-
cilitate cell-cycle-speciﬁc binding to centromere-associated
factors, although the nature of these factors and the mech-
anisms involved remain to be determined (12,54). It is rea-
sonable to assume that in trypanosomes interactions with
centromeric components, conserved between T. brucei and
T. cruzi, are involved in the recruitment and activation of
Topo-II. DNA sequence per se is unlikely to have a direct
role in this process. In T. cruzi, Topo-II activity is focussed
at chromosomal loci that are required for mitotic stability
(28). A central feature of these domains, which are
situated between directional gene clusters, is the presence
of a GC-rich island (11–16kb) composed predominantly
of degenerate retroelements, including the non-LTR retro-
transposon L1Tc. In T. brucei, Topo-II activity (resulting
from the endogenous or the T. cruzi enzyme) is also
associated with regions between directional gene clusters
which are present once per chromosome. These regions
contain transposable elements belonging to the ingi
clade, and in addition, arrays of AT-rich repeat elements
that stretch over several kilobases (29). Although there is
some degree of sequence conservation between ingi and
L1Tc retrotransposons, particularly at the extreme
50-end (55), the widespread abundance of these retroele-
ments at various sites throughout the parasite genome
would argue against a centromere-speciﬁc function based
on a conserved DNA sequence. Identifying the mechan-
isms involved in the centromeric recruitment of Topo-II
will require more information on the organization and
structure of the trypanosome centromere/kinetochore
complex. Such insights will have important implications
for our understanding of basic parasite biology, and in a
more general context, the evolution of the segregation
machinery.
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